The future of multiple sclerosis: Progression focused therapies and RWE
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system (CNS)...
Menopause at a turning point: RWD matters more than ever
A recent CNBC article used HealthVerity real-world data (RWD) to highlight a shortage of estrogen patches that is visible in RWD as demand for menopause support skyrockets. Menopause affects millions of women, yet it has long remained one of the...
Connecting healthcare data to digital campaigns: Solving the attribution challenge
Launching a pharmaceutical marketing campaign takes months of planning, creative development and...
Mitigating data disruptions in open claims datasets
Healthcare data now accounts for approximately 30% of global data volume and with this surge in...
What Medicare's GLP-1 expansion reveals about the future of payer access
On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare Bridge...
An integrated approach for deeper insight with both open and closed claims data
Pharma teams are under sharper financial scrutiny and policy pressure than they've been in years,...
Beyond reach: How real-world signals reshape healthcare audience targeting
Why most syndicated healthcare audiences fall short Claims data is the foundation of any credible...
Menopause at a turning point: RWD matters more than ever
A recent CNBC article used HealthVerity real-world data (RWD) to highlight a shortage of estrogen...
Subtler scopes: Where IRA drug negotiations meet Part D redesigns
Understanding how the IRA’s multiple provisions interact to induce cost-related change The...
Navigating the impacts of the Inflation Reduction Act (IRA): Strategic considerations for pharma
With a few years now into the enactment of the Inflation Reduction Act (IRA), the law continues...
TrOOPs: Tracking cost implications under IRA Part D reforms
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...